Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This report details a case of hair, nail, and pigmentary disorders occurring 10 months after starting abemaciclib for metastatic breast cancer, highlighting that cutaneous side effects, although less frequent, can lead to discontinuation in 25% of cases.

This study found that CDK4/6 inhibitors in hormone-positive metastatic breast cancer were linked to increased risks of fatigue, alopecia, and stomatitis compared to placebo.

This review discusses the use of CDK4/6 inhibitors with endocrine therapy in treating women with HR+ HER2- advanced breast cancer, but it reports no new clinical findings.

This study found that CDK4/6 inhibitors for HR+/HER2- advanced breast cancer are linked to typical adverse events such as fatigue and neutropenia, while also identifying unexpected reactions, highlighting potential safety concerns in their real-world use.

In this study, the researchers found that different CDK4/6 inhibitors used in treating HR+/HER2- advanced breast cancer have varying safety profiles and impacts on patient quality of life.